The company intends to use the funds to expand their team, launch their first solution in 2022 ,and acceòeratyei the development of its pipeline.
Led by CEO Dr. Tobias Werk, Bionter aims to innovate particle testing. Its first product is a particle counter that is fully automated and allows non-destructive sample testing. The complete solution includes a particle counter supported with single-use consumables, maintenance and training, applicable for biotech’s drug product sector and based on a new combination light obscuration technology and smart automation.Bionter’s particle counter is also compliant to current USP/EP/JP regulations familiar with manufacturers.The company has completed development of its patented technology and will launch it end of May 2022.
28/04/2022
